"If we see a treatment is bringing the PSA down rapidly, that's obviously a response," she said. "But if it's not changing, or increasing, we should consider switching treatments."
If prostate cancer is suspected, the patient must undergo a biopsy to determine if it is present.
An alternative to biopsy is showing much promise, Slovin noted.
Using an MRI screening of the patient in tandem with an endorectal probe -- a rubber, gel-filled "finger" that presses against the rectal wall -- doctors are getting astonishing results, she said.
"You can get an almost textbook picture of what's on the other side of the rectal wall," she said. "It shows if cancer has spread, and how invaded the prostate is. It's also minimally invasive compared with biopsies."
More information
To learn more about prostate cancer, visit the U.S. National Cancer Institute.
SOURCES: Howard Soules, Ph.D., executive vice president, the Prostate Cancer Foundation, Santa Monica, Calif.; Susan Slovin, M.D., Ph.D., chairwoman of the Scientific Advisory Board for the National Prostate Cancer Coalition, an assistant member of the Genitourinary Oncology Service at Memorial Sloan-Kettering Cancer Center, and an assistant professor at New York Hospital-Weill Medical College, New York City; American Cancer Society; National Cancer Institute
| Copyright©2007 ScoutNews,LLC. All rights reserved |